Zobrazeno 1 - 10
of 181
pro vyhledávání: '"Pi 3 kinase"'
Autor:
Satya P. Kunapuli, Carol Dangelmaier
Publikováno v:
Platelets
PI-3 Kinase plays an important role in platelet activation mainly through regulation of RASA3. Akt phosphorylation is an indicator for the activity of PI3 kinase. The aim of this study is to characterize the pathways leading to Akt phosphorylation in
Publikováno v:
The FEBS Journal
The phosphoinositide 3-kinase (PI3K) family of lipid-modifying enzymes plays vital roles in cell signaling and membrane trafficking through the production of 3-phosphorylated phosphoinositides. Numerous studies have analyzed the structure and functio
Publikováno v:
Neuro Oncol
Virtually all primary glioblastomas have aberrant activation of the PI 3-kinase pathway through mutational inactivation of tumour suppressors such as PTEN and/or mutational activation of oncogenes. Most glioblastomas also overexpress the Rac guanine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58fbf7fa7b1aff836443145562a44d2
https://europepmc.org/articles/PMC6847169/
https://europepmc.org/articles/PMC6847169/
Publikováno v:
European Heart Journal. 40
Rationale Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling in pulmonary arterioles. Increased activation of receptor tyrosine kinase (RTK)-mediated signaling pathways lead to increased proliferation and chemotaxis of pulm
Autor:
Martin Mollenhauer, Stephan Baldus, Dennis Mehrkens, Eva Berghausen, Marius Vantler, M Zierden, Stephan Rosenkranz, Matti Adam
Publikováno v:
European Heart Journal. 40
Background The pathobiology of aortic aneurysms is characterized by vascular inflammation, extracellular matrix degeneration, and particularly by loss and dedifferentiation of vascular smooth muscle cells (SMCs). In SMCs, the PI 3-kinase isoform p110
Autor:
Bhupal P. Bhetwal, Rajashree Thirumeni
Publikováno v:
The FASEB Journal. 34:1-1
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma
Publikováno v:
Cancer Chemotherapy and Pharmacology. 75:595-608
SF1126 is a vascular-targeted pan-PI-3K inhibitor prodrug with antitumor and antiangiogenic activity and has completed phase I clinical trial in solid tumors and B-cell malignancies. In this study, we investigated the effect of SF1126 on hypoxic HIF-
Autor:
Kyung Sik Yoon, Insug Kang, Young Taek Oh, Ju Hie Lee, Joohun Ha, Hyung Hwan Baik, Wonchae Choe, Jung Yeon Lee, Sung-Soo Kim, Bong Sook Jhun
Publikováno v:
Neuroscience Letters. 712:134486
Publikováno v:
Gastroenterology. 152:S12-S13